YTD stock performance of biopharma companies working on COVID March 2020

Of the U.S. biopharmaceutical companies currently developing treatments or vaccines targeting the COVID-19 infection caused by coronavirus, Vir Biotechnology Inc.'s shares have increased by 279 percent as they are in the midst of preclinical testing monoclonal antibodies as a treatment for this disease. This statistic shows the year-to-date stock performance of select biopharmaceutical companies working on COVID-19 treatments or vaccines in the U.S. as of March 11, 2020.

Year-to-date stock performance of select U.S. biopharmaceutical companies working on COVID-19 treatments or vaccines as of March 11, 2020

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2020

Region

United States

Survey time period

as of March 11, 2020

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Coronavirus (COVID-19) in the U.S."

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.